For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched treatment-outcome population.
Reported findings. No benefit claim from this context reference.
Nonresponse. Not reported in reviewed excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Context citations do not fill outcome-evidence gaps.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Identity context
Identification of Peptide Doping Substances Distributed through the Internet
Two labelled preparations within 17 internet-purchased samples in a 2014 analytical study.
Reported findings. No measured therapeutic benefit; identity/quality context only.
Nonresponse. Claimed compound not detected in one PEG-MGF-labelled sample; the other mainly contained GHRP-2.
Harms. No measured human harms; sampled mislabelling is an identity finding.
Limits. Two historical samples do not establish current catalog lot identity or supplier failure rates. Intended MGF 24-mer YQPPSTNKNTKSQRRKGSTFEERK–PEG is described, not a successfully tested conjugate molecular weight/attachment site. No biological PEG-MGF effect, efficacy, half-life or lymphoma causation was measured.
Preparation: Two historical internet-purchased PEG-MGF-labelled vials; intended conjugate not analytically established. Route: HPLC/high-resolution mass spectrometry; no therapeutic administration.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human report
Public PEG-MGF arm-size report in promotional forum thread
One public firsthand account; identity and clinical outcomes unverified.
Reported findings. Reported about2inches arm-size increase while using PEG-MGF during recovery from a forearm sprain; measurement not independently verified.
Nonresponse. Defined PEG-MGF nonresponse not described.
Harms. PEG-MGF adverse effects not described; fasting-related headache belongs to a separate ipamorelin discussion.
Limits. Same reporter describes interspersed TB500 and heavier training; pain relief attributed to TB500 is not assigned to PEG-MGF. Forum thread advertises a vendor coupon, and reporter has moderator status; commercial relationships unverified. Quoted repetitions by another forum account do not create an independent report. Self-selection, reporting and preparation uncertainty prevent causal proof or established safety.
Preparation: Named PEG-MGF; PEG linkage, preparation, batch and catalog equivalence unverified. Route: Injection described; specific clinical route and depth unresolved.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.